MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
Posted on: Friday, 16 May 2008, 09:01 CDT
MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com/. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/.
MAP Pharmaceuticals, Inc.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122,ljohnson@mappharma.com
Web site: http://www.mappharma.com/
Source: PRNewswire-FirstCall
Related Articles
- MAP Pharmaceuticals Reports First Quarter of 2009 Financial Results
- MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
- MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
- AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
- MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
- MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
- MAP Pharmaceuticals to Host Conference Call on Friday, December 19 to Discuss Worldwide Collaboration with AstraZeneca for UDB
- AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide
- MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Trial of Unit Dose Budesonide in Children With Asthma
- MAP Pharmaceuticals Announces Expanded Development Agreement With Elan Drug Technologies
 |
 |
User Comments (0)
RSS Feeds